(Q37866785)

24 August 2017

1 reference

title

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer (English)

1 reference

24 August 2017

Feng Yang

1

1 reference

24 August 2017

Chen Jin

2

1 reference

24 August 2017

Yong-jian Jiang

3

1 reference

24 August 2017

Ji Li

4

1 reference

24 August 2017

Yang Di

5

1 reference

24 August 2017

De-Liang Fu

6

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

541-549

1 reference

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Review: side effects of approved molecular targeted therapies in solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Emergency surgery in the era of molecular treatment of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Quantifying hypertension in patients with cancer treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Sources of variability in blood pressure measurement using the Dinamap PRO 100 automated oscillometric device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Home blood-pressure monitoring in patients receiving sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Chemotherapy agents and hypertension: a focus on angiogenesis blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Circulating angiogenic factors and the risk of preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble flt-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Tumor microenvironment modifications induced by soluble VEGF receptor expression in a rat liver metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.171

21 January 2018

Identifiers

DOI

10.1586/ERA.10.171

1 reference

24 August 2017

1 reference